{"id":144,"date":"2008-12-08T15:47:27","date_gmt":"2008-12-08T15:47:27","guid":{"rendered":"http:\/\/cardiophile.info\/?p=144"},"modified":"2008-12-08T15:47:27","modified_gmt":"2008-12-08T15:47:27","slug":"ranolazine-a-new-antianginal-agent","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/","title":{"rendered":"Ranolazine &#8211; antianginal agent"},"content":{"rendered":"<p><iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/ld0UN0sPBto\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\"><\/iframe><\/p>\n<h2><span style=\"color: #008000;\">Ranolazine &#8211; antianginal agent<\/span><\/h2>\n<p>Ranolazine, an antianginal agent, is a piperazine derivative, which has been approved in US for treatment of chronic stable angina pectoris as combination therapy when angina is not adequately controlled with conventional drugs. An extended release preparation has been developed to facilitate twice-daily administration. Therapy is initiated with 500 mg twice daily and can be increased to 1000 mg twice daily if needed.<\/p>\n<p><strong>Mechanism of action of ranolazine<\/strong><\/p>\n<p>The main action of ranolazine is that it blocks late sodium currents in ischemic conditions and prevents excess calcium entry into the myocardial cells. This is because the blockage of late sodium current reduces the amount of sodium available for the functioning of sodium-calcium exchanger which facilitates the entry of calcium into the cell.<br \/>\nIn addition, ranolazine is also a partial fatty acid oxidation inhibitor, inhibiting the beta oxidation of fatty acids. This causes a shift of myocardial energy substrate from fatty acids to glucose. Anaerobic glycolysis needs less number of oxygen for production of ATP molecules. Hence shift of myocardial metabolism towards glucose utilisation is beneficial to the ischemic myocardium.<\/p>\n<p>Ranolazine is hemodynamically neutral and does not produce any significant alteration in heart rate or blood pressure.<\/p>\n<p><strong>Pharmacokinetics of ranolazine<\/strong><\/p>\n<p>Pharmacokinetics of ranolazine is altered in mild, moderate and severe renal impairment. But mild hepatic impairment has no significant effects on pharmacokinetics of ranolazine. Moderate and severe hepatic impairment alters Cmax and AUC (area under the curve) of ranolazine. Gender, heart failure and diabetes has no effect on pharmacokinetics of ranolazine.<\/p>\n<p><strong>Effect of ranolazine on QT interval<\/strong><\/p>\n<p>Minor increases in QTc interval with ranolazine has been reported in MARISA and CARISA trials. Increases in QTc ranged from 6.1 to 9.2 ms. But no discontinuation of drug was required because of QTc prolongation. No cases of torsades de pointes were reported with ranolazine. The cellular electrophysiology underlying the QTc effect of ranolazine appears to be different from that of drugs known to cause torsade de pointes. Even though ranolazine does prolong action potential duration and QT interval, it has not been shown to induce early afterdepolarizations like other QT prolonging drugs. Ranolazine does not increase dispersion of ventricular repolarization. Still, it is prudent to exercise caution while using ranolazine along with other drugs which are likely to prolong the QT interval.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ranolazine, a new anti-anginal agent is a piperazine derivative, for treatment of chronic stable angina pectoris as combination therapy when angina is not adequately controlled with conventional drugs.<\/p>\n","protected":false},"author":1,"featured_media":37957,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-144","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ranolazine - antianginal agent: piperazine derivative<\/title>\n<meta name=\"description\" content=\"Ranolazine - antianginal agent is a piperazine derivative, for treatment of chronic stable angina pectoris as combination therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ranolazine - antianginal agent: piperazine derivative\" \/>\n<meta property=\"og:description\" content=\"Ranolazine - antianginal agent is a piperazine derivative, for treatment of chronic stable angina pectoris as combination therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2008-12-08T15:47:27+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ranolazine-a-new-antianginal-agent\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ranolazine-a-new-antianginal-agent\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Ranolazine &#8211; antianginal agent\",\"datePublished\":\"2008-12-08T15:47:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ranolazine-a-new-antianginal-agent\\\/\"},\"wordCount\":383,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ranolazine-a-new-antianginal-agent\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ranolazine-a-new-antianginal-agent\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ranolazine-a-new-antianginal-agent\\\/\",\"name\":\"Ranolazine - antianginal agent: piperazine derivative\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ranolazine-a-new-antianginal-agent\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ranolazine-a-new-antianginal-agent\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2008-12-08T15:47:27+00:00\",\"description\":\"Ranolazine - antianginal agent is a piperazine derivative, for treatment of chronic stable angina pectoris as combination therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ranolazine-a-new-antianginal-agent\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ranolazine-a-new-antianginal-agent\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ranolazine-a-new-antianginal-agent\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ranolazine-a-new-antianginal-agent\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ranolazine &#8211; antianginal agent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ranolazine - antianginal agent: piperazine derivative","description":"Ranolazine - antianginal agent is a piperazine derivative, for treatment of chronic stable angina pectoris as combination therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/","og_locale":"en_US","og_type":"article","og_title":"Ranolazine - antianginal agent: piperazine derivative","og_description":"Ranolazine - antianginal agent is a piperazine derivative, for treatment of chronic stable angina pectoris as combination therapy.","og_url":"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2008-12-08T15:47:27+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Ranolazine &#8211; antianginal agent","datePublished":"2008-12-08T15:47:27+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/"},"wordCount":383,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/#primaryimage"},"thumbnailUrl":"","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/","url":"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/","name":"Ranolazine - antianginal agent: piperazine derivative","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/#primaryimage"},"thumbnailUrl":"","datePublished":"2008-12-08T15:47:27+00:00","description":"Ranolazine - antianginal agent is a piperazine derivative, for treatment of chronic stable angina pectoris as combination therapy.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/ranolazine-a-new-antianginal-agent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Ranolazine &#8211; antianginal agent"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=144"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/144\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}